Medical Oncology

Academic Roundtable

Questions discussed in this category

What salvage chemotherapy, if any, would you recommend for a patient with primary refractory DLBCL who progressed after two cycles of R-CHOP?

5 Answers available

How does your surveillance for DLBCL change given the new role of CAR-T in 2nd line treatment?

How do you assess if a patient may be a candidate for CAR-T cell therapy?

3 Answers available

What is the best approach for patients with DLBCL with early relapse (< 6 months) after initially attaining a CR with 6 cycles RCHOP?

Does this differ for a patient who had a longer remission before relapse?

4 Answers available

How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

4 Answers available

Papers discussed in this category

N Engl J Med, 2021 Dec 11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Lancet,

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Lancet Oncol, 2020 Jun 05

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

J Clin Oncol, 2019 Nov 06

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Medical Oncology

Academic Roundtable

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology